Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 11, 2015

Primary Completion Date

March 7, 2018

Study Completion Date

April 16, 2018

Conditions

Colorectal Cancer

Interventions

DRUG

Vorinostat

400mg by mouth daily

DRUG

Hydroxychloroquine

600mg by mouth daily

DRUG

Regorafenib

160 mg by mouth daily

Trial Locations (1)

Cancer Therapy and Research Center University of Texas Health Science Center San Antonio, San Antonio

All Listed Sponsors

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02316340 - Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | Biotech Hunter | Biotech Hunter